Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...
After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...
A new study has revealed that the gene HMGN1 is a key driver of congenital heart defects (CHDs) in Down syndrome. Using ...
Virginia Tech scientists found that age-related memory loss stems from molecular changes in the brain. Memory decline might ...
Research from UChicago dissects how a single genetic switch helps butterflies mimic wing patterns of other species to protect ...
A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...
Chowhound on MSN
Why Chocolate Is So Expensive (And How Researchers Might Put A Stop To Rising Prices)
Chocolate prices have been rising due to complications in the supply chain, but Penn State researchers have made a ...
Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ...
Intellia Therapeutics, Inc. is rated Hold due to uncertainty from dosing pause in its MAGNITUDE program for ATTR. Learn more ...
Nex-z is one of two late-stage projects on the go at Intellia, a specialist in CRISPR gene-editing co-founded by Nobel Prize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback